摘要
目的对顽固性心力衰竭患者使用人冻干重组脑利钠肽联合小剂量多巴酚丁胺的疗效进行评估。方法选取顽固性心力衰竭患者120例,随机分为A组、B组和C组各40例,常规基础治疗上,A组给予常规剂量多巴酚丁胺,B组给予人冻干重组脑利钠肽,C组给予人冻干重组脑利钠肽联合小剂量多巴酚丁胺。比较三者临床疗效、左房内径、左心室舒张期末径、左心室射血分数、血浆脑利钠肽等指标。结果 C组对顽固性心力衰竭的疗效明显高于A组、B组;与治疗前比较,三组在治疗后72h左室内径减小,左室射血分数提高,血浆BNP水平下降,但以C组效果尤佳。结论人冻干重组脑利钠肽联合小剂量多巴酚丁胺治疗顽固性心力衰竭效果显著,副作用小。
Objective To evaluate the effect of the patients with Refractory heart failure using Lyophilized recombinant human brain natriuretic peptide jointing low-dose Dobutamine. Methods 120 patients with Refractory heart failure were randomly divided into A group(n=40), B group(n=40) and C group(n=40), A group was treated with conventional-dose Dobutamine, B group was treated with Lyophilized recombinant human brain natriuretic peptide. C group was treated with Lyophilized recombinant human brain natriuretic peptide jointing low-dose Dobutamine. Three groups were compared the effect of heart failure treatment, LAD,LVEDD,LVEF and plasma BNP level.Results Compared with A group and B group, C group's treatment of arrhythmia get best results. Compared with before treatment,three group's LAD ,LVEDD and plasma BNP level decreased,E / A improved, the effect of group C is especially obvious. Conclusion It is effective and safe for the patients with Refractory heart failure to use Lyophilized recombinant human brain natriuretic peptide jointing low-dose Dobutamine.
出处
《中国医药指南》
2013年第34期49-50,共2页
Guide of China Medicine
关键词
顽固性心力衰竭
人冻干重组脑利钠肽
多巴酚丁胺
Refractory heart failure
Lyophilized recombinant human brain natriuretic peptide
Dobutamine